TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05526885

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CAD4TB
Description: A posterior anterior digital chest X-ray incoporated in a mobile diagnostic unit is analysed by CAD4TB version 7 (Delft Imaging, NL). A trained and qualified person in compliance with national regulations will operate the digital chest X-ray.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CAD4TB
Description: A posterior anterior digital chest X-ray incoporated in a mobile diagnostic unit is analysed by CAD4TB version 7 (Delft Imaging, NL). A trained and qualified person in compliance with national regulations will operate the digital chest X-ray.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: POC-CRP
Description: A quantitative POC-CRP LumiraDx (LumiraDx Limited, UK) triage test will be performed by finger-prick if CAD4TB scores is within the defined threshold window of study approach 2 triage testing

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF Ultra
Description: Depending on CAD4TB (approach 1 \& 2) or POC-CRP score (approach 2) a confirmatory Xpert MTB/RIF Ultra(Cepheid, USA) rapid sputum molecular testing follows for both Mycobacterium tuberculosis complex and rifampicin resistance;

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF Ultra
Description: Depending on CAD4TB (approach 1 \& 2) or POC-CRP score (approach 2) a confirmatory Xpert MTB/RIF Ultra(Cepheid, USA) rapid sputum molecular testing follows for both Mycobacterium tuberculosis complex and rifampicin resistance;
Study: NCT04865770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Semaglutide)
Description: Placebo (Semaglutide) given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
Study: NCT05909397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471 (PF-07850327)
Description: Pharmaceutical form: Tablets. Route of Administration: Oral

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Pharmaceutical form: Capsules. Route of Administration: Oral.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Pharmaceutical form: Capsules. Route of Administration: Orally

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Pharmaceutical form: Capsules. Route of Administration: Oral.
Study: NCT04768842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC.
Study: NCT04958330

Intervention type: PROCEDURE
Intervention: lateral prostate capsule sparing
Description: When resect the bladder and prostate, the lateral prostate capsule will be preserved.
Study: NCT05535543

Intervention type: PROCEDURE
Intervention: Prone Positioning
Description: Patients will be turned to prone position and they will be left in prone position for a duration of at least 16 hours to a maximum of 24 hours. This duration is recommended by the ARDS guidelines.
Study: NCT05190224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization of the deep peroneal, posterior tibial and medial medial and lateral dorsocutaneous nerves.
Description: In lateral decubitus the patient with the help of the clinician will perform neuromeningeal mobilization of the posterior tibial dorsocutaneous lateral, intermediate and medial nerves and deep peroneal nerve too.
Study: NCT05882201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia Iliaca compartment block group
Description: Group FICB Fascia: with the patient supine, the skin was prepped and draped with alcohol solution 70%,~. A 22-G needle will be visualized entering the fascia Lata and the FI. bupivacaine, up to 2.5mg/kg of lean body weight with a volume of injectate of .5 ml/kg up to 40 ml will be injected after aspiration beneath the fascia Lata.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral nerve block group
Description: ✓ Group FNB; With the patient supine, the skin will be prepped and draped with alcohol solution 70% The nerve in the crosssection is a triangular white structure lateral to the femoral artery. Ultrasoundallows direct visualization of the needle and nerve as well as real-time monitoring of the injection of local anesthetic. An in-plane approach will be used to direct needle placement to the femoral nerve and inject after aspiration with bupivacaine, up to 2.5mg/kg of lean body weight with a volume of injectate of .5 ml/kg up to 40ml.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: General care
Description: using ordinary technique
Study: NCT04947254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiandrogen Therapy
Description: Given ADT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Given ADT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT05774483

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel Node Biopsy
Description: The Sentinel node will be localized after injecting peritumoral nano colloid followed by dynamic lymphoscintigraphy and SPECT localization. Methylene blue or indocyanine green may be used but not mandatory as an adjunct for lymphoscintigraphy for node localization. Intraoperatively the node will be identified using a hand-held gamma probe. The sentinel node will be processed on a frozen section, histopathological processing with serial step sectioning, and immunohistochemistry. If reported as metastatic, then a single-stage or second-stage completion neck dissection will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited Elective Neck Dissection
Description: Patients who are allocated to the limited END arm will undergo dissection of level I, IIa and III/IV nodes sparing level IIb. Level IIa will be subjected to a frozen section and if reported as metastatic will mandate clearance of level IIb.
Study: NCT04875715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond Oil
Description: Almond oil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroquinone Topical
Description: Hydroquinone 2% cream
Study: NCT05164302

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: Auricular acupuncture is a method for diagnosing and treating physical and psychosomatic dysfunctions by stimulating a specific point in the ear. To conducting this intervention, we use press tack needles to perform auricular acupuncture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: Auricular acupuncture is a method for diagnosing and treating physical and psychosomatic dysfunctions by stimulating a specific point in the ear. To conducting this intervention, we use press tack needles to perform auricular acupuncture.
Study: NCT04739462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Platform
Description: All participants randomized to the intervention group will receive 2-4 informational texts each week and will also receive interactive health screening questions throughout enrollment. A participant will also receive appointment reminder texts. All SMS text messages will be transmitted through a local organization known as The Medical Concierge Group (TMCG) via an electronic system that allows for bulk messaging. TMCG also staffs a 24-hour call line for those using TMCG services to call in for medical related questions. This call line is staffed by doctors and nurses; SMS Maama participants randomized to the interventional group will be able to access this call line free of charge as part of their enrollment in SMS Maama.
Study: NCT05672212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANI (Analgesia/Nociception Index) monitoring
Description: Intraoperative analgesia was provided by injection of sufentanil, which was performed according to ANI monitor.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard monitoring
Description: Intraoperative analgesia was provided by injection of sufentanil, which was performed according to the clinician's assessment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Sufentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil
Study: NCT05186337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FROA-BD programme
Description: The experimental group (n=42) will receive a 4-month intervention consisting of 32 sessions of treatment.
Study: NCT05158101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT06487598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inj insulin to one group
Description: One group- only inj insulin for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inj insulin to one group
Description: One group- only inj insulin for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inj Insulin with Tab Nisha-Amalaki 500 mg twice a day
Description: second group- Inj Insulin with Tab Nisha-Dhatri 500 mg twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inj Insulin with Tab Nisha-Amalaki 500 mg twice a day
Description: second group- Inj Insulin with Tab Nisha-Dhatri 500 mg twice a day
Study: NCT06355934

Intervention type: OTHER
Intervention: no intervention
Description: not applicable, this is an observational retrospective data analysis study; no interventions in the study

Intervention type: OTHER
Intervention: no intervention
Description: not applicable, this is an observational retrospective data analysis study; no interventions in the study

Intervention type: OTHER
Intervention: no intervention
Description: not applicable, this is an observational retrospective data analysis study; no interventions in the study

Intervention type: OTHER
Intervention: no intervention
Description: not applicable, this is an observational retrospective data analysis study; no interventions in the study

Intervention type: OTHER
Intervention: no intervention
Description: not applicable, this is an observational retrospective data analysis study; no interventions in the study

Intervention type: OTHER
Intervention: no intervention
Description: not applicable, this is an observational retrospective data analysis study; no interventions in the study
Study: NCT06651229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-90189892
Description: JNJ-90189892 will be administered.
Study: NCT04947137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Study: NCT06613685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1720
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-4182
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1720/GS-4182 FDC
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1720/GS-4182 FDC
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1720/GS-4182 FDC
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match BVY
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Match GS1720/GS-4182 FDC
Description: Tablets administered orally without regard to food
Study: NCT06624514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Group
Description: Implicit approach bias is the behavioral action tendency to be faster to approach rather than avoid cues for a stimulus category. The Approach-Avoidance Task (AAT)is a computerized program in which participants make approach or avoidance movements in response to an irrelevant feature of an image presented on a computer screen (e.g., push when in portrait, pull when in landscape). The intervention in this study is a treatment version of the AAT used as an Approach Bias Modification (ABM) intervention, to retrain participants' implicit biases toward or away from stimuli by presenting the target stimuli predominantly in one format (e.g., push or pull).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training Group
Description: A sham-training control condition
Study: NCT06625671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-2304
Description: DB-2304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-2304
Description: DB-2304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-2304
Description: DB-2304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-2304
Description: DB-2304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-2304
Description: DB-2304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT05959785

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Basic and light cervical mobilization exercises
Description: This group of exercises will be made up of a series of cervical mobilization exercises that are performed without pain, smooth, controlled by the patients, and without forcing the angulations. They are performed seated, with the arms extended along the body and forearms and hands resting on the legs. The chair must be firm and comfortable. Head movements to the right and left, right and left lateral flexion of the cervical region, cervical flexion and extension will be performed. This exercise will be performed for 5 minutes 3 times a day and beginning in the first 24 postoperative hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal or diaphragmatic breathing exercises
Description: The first abdominal or diaphragmatic breathing exercises will be carried out in a lying position, with the back well supported on a comfortable and firm surface, and with hips and knees flexed and feet supported. The patients take deep breaths, taking air raising the abdomen towards the ceiling, without raising the back from the horizontal plane. During expiration the navel will lower posteriorly and rise towards the thoracic region. For the second abdominal or diaphragmatic breathing exercise, the patient is seated on a firm and comfortable surface, with hips and knees flexed and feet supported. An inspiratory movement will be made in which the patient's navel will be moved outward, away from the spine. During expiration, the navel will go in the direction of the patient's spine and will rise in the direction of the thorax.
Study: NCT06625671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04914884

Intervention type: DIAGNOSTIC_TEST
Intervention: intraocular fluid detection
Description: This study mainly verified the use of molecular biology technology to detect the changes of VCAM, ICAM-1 and other cytokines, bacteria, viruses, fungi, Toxoplasma gondii IgG in patients' intraocular fluid, including aqueous humor and vitreous humor, so as to timely judge the etiology and progress of endophthalmitis, and provide reference for diagnosis and treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: intraocular fluid detection
Description: This study mainly verified the use of molecular biology technology to detect the changes of VCAM, ICAM-1 and other cytokines, bacteria, viruses, fungi, Toxoplasma gondii IgG in patients' intraocular fluid, including aqueous humor and vitreous humor, so as to timely judge the etiology and progress of endophthalmitis, and provide reference for diagnosis and treatment.
Study: NCT04448834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: liposomal vincristine 2.25 mg/m2 weekly x 3 per cycle (weeks 3-5 in cycle 1 and 2-4 in subsequent cycles)
Study: NCT05387473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT-I) integrated in best-evidence usual care (CBTi-UC)
Description: In the first two weeks, the participants will receive three sessions of education and advice based on current best-practice guidelines. In the following three weeks, the participants will be provided with once weekly exercise therapy and once weekly CBT-I. This is then spread out more over the next five weeks in which participants will receive once weekly sessions of either CBT-I or exercise therapy in alternating order. In the last four weeks of the intervention period, the participants will receive once weekly exercise therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best-evidence usual care (UC) plus information sessions
Description: In the first two weeks, the participants will receive three sessions of education and advice based on current best-practice guidelines. In the following three weeks, the participants will be provided with once weekly exercise therapy and once weekly general information sessions (general education sessions in line with recommendations from best-practice guidelines and recent evidence). This is then spread out more over the next five weeks in which participants will receive once weekly sessions of either CBT-I or exercise therapy in alternating order. In the last four weeks of the intervention period, the participants will receive once weekly exercise therapy.
Study: NCT05711056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sociobehavioral Intervention
Description: Utilizes two primary evidence-based strategies:~* Delivering OUD consultation via telemedicine, which has been demonstrated to be a safe and effective means for initiating MOUD with buprenorphine; and,~* Incorporating psychosocial support in the form of PRC, whose involvement in patient care is associated with increased treatment retention and MOUD initiation.
Study: NCT05655286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 38% SDF treatment
Description: Children with active caries will receive 38% silver diamine fluoride treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 38% SDF treatment
Description: Children with active caries will receive 38% silver diamine fluoride treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: not to rinse for at least 30 minutes after SDF treatment
Description: After receiving 38% silver diamine fluoride treatment, Children will be asked not to rinse their mouths for at least 30 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rinse mouth immediately after SDF treatment
Description: After receiving 38% silver diamine fluoride treatment, Children will be asked to rinse their mouths immediately.
Study: NCT06226805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-031
Description: Solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride for injection
Study: NCT06625671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT05556096

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ALXN1720
Description: Combination product consisting of syringe prefilled with ALXN1720.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Combination product consisting of syringe prefilled with placebo.
Study: NCT06755892

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ColMSM-HL
Description: Participants will test continuous administration of investigational product for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo syrup
Description: Participants will test continuous administration of placebo product for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ColMSM-LH
Description: Participants will test continuous administration of investigational product for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ColMSM-LL
Description: Participants will test continuous administration of investigational product for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Col-L
Description: Participants will test continuous administration of investigational product for 16 weeks.
Study: NCT06760312

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal shaping with Continuous Rotation
Description: The root canal shaping is conducted with a continuous rotation kinematic.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal shaping with Apical Reverse
Description: The root canal shaping is conducted with a apical reverse kinematic.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal shaping is conducted with Apical slow-down kinematic.
Description: The root canal shaping is conducted with a apical slow-down kinematic.